Related Experiment Video

Updated: Jun 29, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Comparative effects of atrial polypeptide and neurohormone C on the interaction of factor Xa with antithrombin III

Martin H Coggin1, Rima M Srapionian, Arthur S Brecher

  • 1Department of Biological Sciences, Bowling Green State University, Bowling Green, OH 43403, USA.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|October 4, 2008
PubMed

Insights

Atrial polypeptide alters human factor Xa (FXa) and antithrombin III (ATIII) interactions, promoting complex degradation or formation depending on preincubation. Neurohormone C enhances complex formation and stability, potentially inhibiting FXa activity.

Area of Science:

  • Biochemistry and Molecular Biology
  • Hematology and Coagulation Studies

Background:

  • The interaction between human factor Xa (FXa) and human antithrombin III (ATIII) is crucial for regulating blood coagulation.
  • Atrial polypeptide and neurohormone C are endogenous signaling molecules with potential roles in physiological processes, including hemostasis.

Purpose of the Study:

  • To investigate the effects of atrial polypeptide and neurohormone C on the interaction dynamics between FXa and ATIII.
  • To elucidate the molecular mechanisms by which these peptides modulate FXa-ATIII complex formation and stability.

Main Methods:

  • Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was employed to detect and quantify various FXa-ATIII complexes and related species.
  • Analysis included identification of 1st, 2nd, and 3rd degree duplex complexes, modified ATIII (ATIIIM), native ATIII, free FXa isoforms, and FXa degradation products.

Main Results:

  • Atrial polypeptide induced a shift from FXaalpha-ATIII to FXabeta-ATIII complexes, increased ATIIIM and FXagamma, suggesting complex degradation.
  • Atrial polypeptide promoted FXa-ATIII complex formation when preincubated with ATIII or added early to mixtures, but inhibited it when preincubated with FXa.
  • Neurohormone C increased total complex formation, decreased ATIIIM and FXagamma, and stabilized FXa-ATIII complexes, suggesting suppression of FXa's proteolytic activity.

Conclusions:

  • Atrial polypeptide exhibits contrasting effects on FXa-ATIII interactions, potentially promoting complex formation or degradation based on preincubation conditions.
  • Neurohormone C appears to enhance the stability of FXa-ATIII complexes, possibly by inhibiting FXa-mediated hydrolysis or autolytic activity.
  • The distinct roles of atrial polypeptide and neurohormone C highlight their complex regulatory influence on the coagulation cascade.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...